MAZE - CIK 0001842295
Maze Therapeutics, Inc. trades as MAZE and has a market capitalization of $1.29 B, making it the #2448 largest US-listed company by market value. In its fiscal 2024 annual report the company posted revenue of $167.50M and net income of -$131.12M. This page tracks Maze Therapeutics, Inc. through 165 SEC filings, with financial statements and metrics updated as new reports are filed.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| EFFECT | - | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-12 |
The largest companies sharing Maze Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.29 B as of 2026-06-10, ranking #2448 among US-listed companies.
Maze Therapeutics, Inc. reported revenue of $167.50M for fiscal year 2024.
In its latest fiscal year Maze Therapeutics, Inc. reported a net loss of $131.12M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.